This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1D09C3

Agennix AG

Drug Names(s): 1D09C3

Description: 1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing effect.

Deal Structure: In April 1999, GPC entered into a collaboration and license agreement with MorphoSys. MorphoSys identified more than a dozen antibodies, from which GPC selected 1D09C3. MorphoSys is entitled to milestone payments upon the occurrence of specified events in the development and commercialization of antibody product candidates resulting from the collaboration. If all milestones were achieved, these milestone payments would total approximately 10 million. MorphoSys is also entitled to receive royalties on net sales of any of these antibody products by GPC. If GPC enters into an agreement with a partner for the commercialization of any of these antibody products, GPC would be obligated to pay MorphoSys a percentage of sublicense fees, milestone payments and royalties.

In February 2009, GPC Biotech and Agennix announced that the companies signed a Business Combination Agreement under which they propose to merge their businesses. The merger of GPC Biotech into Agennix was completed in...See full deal structure in Biomedtracker

Partners: MorphoSys AG


1D09C3 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

[Request a Free Demo] [Subscriber Login] [Search for another drug]